# Ran Nussbaum

> Ran Nussbaum is a Series A investor at Pontifax (Herzliya) backing Biotechnology and Therapeutics. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Pontifax](https://shizune.co/investors/profile/pontifax)
- Location: Herzliya, Israel
- Total investments: 10
- Last investment: Oct 2025
- Lead investor: 40%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/ran-nussbaum-b402566/
- Website: https://x.com/NussbaumRan
- Facebook: https://www.facebook.com/ran.nussbaum

Ran Nussbaum is a Series A investor at Pontifax in Herzliya focused on Biotechnology and Therapeutics. Ran Nussbaum is based out of Herzliya, Tel Aviv, and is the Managing Partner and Co-Founder of Pontifax. Ran previously served as the Board of Director at Keros Therapeutics.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 60% |
| Therapeutics | 3 | 30% |
| Pharmaceutical | 3 | 30% |
| Health Care | 2 | 20% |
| Medical | 1 | 10% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 30% |
| Series C | 3 | 30% |
| Seed | 1 | 10% |
| Series B | 1 | 10% |
| Post-IPO Equity | 1 | 10% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 40% |
| Israel | 2 | 20% |
| France | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Adcytherix | Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC) to treat diseases with a high unmet need, including cancer. | $122.8M | Series A | Oct 16, 2025 |  |
| Kamari Pharma | Kamari Pharma develops innovative treatments for unmet needs and rare diseases in dermatology. | $23M | Series A | Jun 03, 2025 |  |
| Adcytherix | Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC) to treat diseases with a high unmet need, including cancer. | $32.2M | Seed | Jun 11, 2024 |  |
| LB Pharmaceuticals | LB Pharmaceuticals is a development stage life sciences company devoted to commercializing novel and improved versions of successful CNS treatments used extensively overseas but never developed, approved, or marketed in the United States. Its approach is to create a research-focused organization dedicated to generating novel intellectual propertyaround improved versions of these former best-selling drugs. The Company's lead asset is LB-102 (n-Methyl amisulpride) a novel, patented version of amisulpride, one of the most effective drugs ever developed for the treatment of schizophrenia. | $75M | Series C | Jan 24, 2024 |  |
| Graviton Bioscience | Graviton Bioscience is a clinical-stage drug discovery and development firm focused on creating and developing therapies for the treatment of CNS, autoimmune, fibrotic, and other significant disorders in which ROCK2 plays a critical role in pathology. | $39.8M | Venture - Series Unknown | Dec 20, 2022 |  |
| Fore Biotherapeutics | We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $57M | Series C | Sep 21, 2020 |  |
| Keros Therapeutics | Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with a high unmet medical need. Keros is a leader in understanding the role of the Transforming Growth Factor-Beta, or TGF-ß, family of proteins,which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros' lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros' third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. | $56M | Series C | Mar 04, 2020 |  |
| Keros Therapeutics | Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with a high unmet medical need. Keros is a leader in understanding the role of the Transforming Growth Factor-Beta, or TGF-ß, family of proteins,which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros' lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros' third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. | $23M | Series B | Jan 08, 2019 |  |
| Keros Therapeutics | Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with a high unmet medical need. Keros is a leader in understanding the role of the Transforming Growth Factor-Beta, or TGF-ß, family of proteins,which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros' lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros' third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. | $11M | Series A | Nov 09, 2017 |  |
| ArQule | ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin). | $9.5M | Post-IPO Equity |  |  |

10 of 10 investments shown.

## Co-investors
- [Arkin Bio Ventures](https://shizune.co/investors/profile/arkin-bio-ventures) — VC Fund, 3 deals together
- [Partners Innovation Fund](https://shizune.co/investors/profile/partners-innovation-fund) — VC Fund, 3 deals together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 2 deals together
- [Dawn Biopharma](https://shizune.co/investors/profile/dawn-biopharma) — VC Fund, 2 deals together
- [Global health sciences venture fund](https://shizune.co/investors/profile/global-health-sciences-venture-fund) — VC Fund, 2 deals together
- [Medison Pharma](https://shizune.co/investors/profile/medison-pharma) — VC Fund, 2 deals together

## About Pontifax

VC Fund · Herzliya, Israel

Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.

4 contacts available at Pontifax.

| Name | Title | Profile |
| --- | --- | --- |
| Ohad Hammer | Partner | https://shizune.co/investors/profile/ohad-hammer |
| Ran Nussbaum | Managing Partner and Co-Founder | https://shizune.co/investors/profile/ran-nussbaum |
| Tomer Kariv | Co-Founder and Chief Executive Officer | https://shizune.co/investors/profile/tomer-kariv |
| Momi Karako | Partner | https://shizune.co/investors/profile/momi-karako |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Ran Nussbaum invest in?

Ran Nussbaum invests primarily in Biotechnology, Therapeutics and Pharmaceutical startups, most often at Series A and Series C stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ran Nussbaum last invest?

The most recent investment recorded for Ran Nussbaum closed in Oct 2025. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co